Am­gen inks dis­cov­ery deal with Hum­ming­bird; Mer­ck gains pri­or­i­ty re­view for Ebo­la vac­cine

Am­gen has en­list­ed Hum­ming­bird Bio­science on a new an­ti­body dis­cov­ery pact, turn­ing over some nov­el tar­gets to see if the small­er play­er’s “sys­tems bi­ol­o­gy” plat­form can yield bet­ter ther­a­peu­tics. Start­ing with two ini­tial pro­grams with the po­ten­tial to add 10 more over the next six years, Am­gen has ex­clu­sive op­tions to li­cense the re­sult­ing an­ti­bod­ies for $100 mil­lion per project. Hum­ming­bird, which has of­fices in Hous­ton, South San Fran­cis­co and Sin­ga­pore, is al­so re­ceiv­ing an undis­closed up­front and re­search pay­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.